Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Regencell Bioscience ( (RGC) ) is now available.
On June 17, 2025, Regencell Bioscience Holdings Limited announced the effectuation of a 38-for-one forward stock split, initially declared on June 2, 2025. This stock split, issued as a stock bonus, does not alter the company’s name, CUSIP, or trading symbol, and requires no action from shareholders, as adjustments will be automatically reflected in brokerage accounts or through the company’s transfer agent for registered shareholders.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically targeting Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company aims to become a market leader in natural and holistic treatments for neurological disorders globally.
Average Trading Volume: 7,761,408
Technical Sentiment Signal: Buy
Current Market Cap: $29.67B
For detailed information about RGC stock, go to TipRanks’ Stock Analysis page.